Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science

Affiliations

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, 9700 RB Groningen, Netherlands. Electronic address: j.w.c.alffenaar@umcg.nl.
² Maugeri Care and Research Institute, Tradate, Italy.
³ Baylor Research Institute, Dallas, TX, USA.

Comment

Jan-Willem C Alffenaar et al. Lancet Infect Dis. 2017 Sep.

. 2017 Sep;17(9):898.

doi: 10.1016/S1473-3099(17)30449-8.

¹ University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, 9700 RB Groningen, Netherlands. Electronic address: j.w.c.alffenaar@umcg.nl.
² Maugeri Care and Research Institute, Tradate, Italy.
³ Baylor Research Institute, Dallas, TX, USA.

No abstract available

Comment on

Drug-resistant tuberculosis threatens WHO's End-TB strategy.
Mariandyshev A, Eliseev P. Mariandyshev A, et al. Lancet Infect Dis. 2017 Jul;17(7):674-675. doi: 10.1016/S1473-3099(17)30246-3. Epub 2017 May 9. Lancet Infect Dis. 2017. PMID: 28499827 No abstract available.
Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.
Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, Caoili JC, Gler MT, Volchenkov GV, Kazennyy BY, Demikhova OV, Bayona J, Contreras C, Yagui M, Leimane V, Cho SN, Kim HJ, Kliiman K, Akksilp S, Jou R, Ershova J, Dalton T, Cegielski P; Global Preserving Effective TB Treatment Study Investigators. Sharma A, et al. Lancet Infect Dis. 2017 Jul;17(7):707-715. doi: 10.1016/S1473-3099(17)30247-5. Epub 2017 May 9. Lancet Infect Dis. 2017. PMID: 28499828 Free PMC article.